Key statistics
As of last trade OSE Immunotherapeutics SA (0RAD:LSE) traded at 4.39, 3.34% above its 52-week low of 4.25, set on Feb 06, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 4.39 |
| Low | 4.39 |
| Bid | -- |
| Offer | -- |
| Previous close | 4.44 |
| Average volume | 44.60 |
|---|---|
| Shares outstanding | 22.46m |
| Free float | 16.31m |
| P/E (TTM) | -- |
| Market cap | 99.74m EUR |
| EPS (TTM) | -1.59 EUR |
Data delayed at least 20 minutes, as of Feb 10 2026 08:00 GMT.
More ▼
Announcements
- OSE Immunotherapeutics sélectionne la pouchite chronique et l’hidradénite suppurée comme nouvelles indications clés pour Lusvertikimab
- OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
- OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
- OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101)
- Half-Year Report on Liquidity Contract with Invest Securities
- Informations relatives au nombre total de droits de vote et d’actions composant le capital
- Bilan semestriel du contrat de liquidité avec Invest Securities
- OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur
- OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
- OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
More ▼
